Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis S Harris

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry|October 27, 2007
The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: BenzomorphansMatthew D Metcalf, Mario D Aceto, Louis S Harris, et al.
Pharmacology, Biochemistry, and Behavior|September 1, 2012
l-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like activity in miceLaura E Wise, Ishani D Premaratne, Thomas F Gamage, et al.
Molecular Pain|July 26, 2014
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptorTanila Ben Haddou, Davide Malfacini, Girolamo Calo, et al.
Journal of Medicinal Chemistry|April 18, 2003
Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationshipsElisabeth Greiner, Mariana Spetea, Roland Krassnig, et al.
Journal of Medicinal Chemistry|May 28, 2004
Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodimeMariana Spetea, Falko Schüllner, Radu C Moisa, et al.
European Journal of Pharmacology|October 7, 2004
Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonistIvy Carroll, James B Thomas, Linda A Dykstra, et al.
Journal of Medicinal Chemistry|March 4, 2009
Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexaminesGerta Cami-Kobeci, Adrian P Neal, Faye A Bradbury, et al.
Journal of Medicinal Chemistry|October 10, 2012
Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effectsHumphrey A Moynihan, Ian Derrick, Jillian H Broadbear, et al.
Organic & Biomolecular Chemistry|April 5, 2007
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonistsKejun Cheng, In Jong Kim, Mei-Jing Lee, et al.
Journal of Medicinal Chemistry|July 13, 2007
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan seriesAnne-Cécile Hiebel, Yong Sok Lee, Edward Bilsky, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry|October 27, 2007
The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: BenzomorphansMatthew D Metcalf, Mario D Aceto, Louis S Harris, et al.
Pharmacology, Biochemistry, and Behavior|September 1, 2012
l-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like activity in miceLaura E Wise, Ishani D Premaratne, Thomas F Gamage, et al.
Molecular Pain|July 26, 2014
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptorTanila Ben Haddou, Davide Malfacini, Girolamo Calo, et al.
Journal of Medicinal Chemistry|April 18, 2003
Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationshipsElisabeth Greiner, Mariana Spetea, Roland Krassnig, et al.
Journal of Medicinal Chemistry|May 28, 2004
Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodimeMariana Spetea, Falko Schüllner, Radu C Moisa, et al.
European Journal of Pharmacology|October 7, 2004
Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonistIvy Carroll, James B Thomas, Linda A Dykstra, et al.
Journal of Medicinal Chemistry|March 4, 2009
Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexaminesGerta Cami-Kobeci, Adrian P Neal, Faye A Bradbury, et al.
Journal of Medicinal Chemistry|October 10, 2012
Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effectsHumphrey A Moynihan, Ian Derrick, Jillian H Broadbear, et al.
Organic & Biomolecular Chemistry|April 5, 2007
Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonistsKejun Cheng, In Jong Kim, Mei-Jing Lee, et al.
Journal of Medicinal Chemistry|July 13, 2007
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan seriesAnne-Cécile Hiebel, Yong Sok Lee, Edward Bilsky, et al.
Pageof 2